(Reuters) -MeiraGTx Holdings has signed a deal with Eli Lilly, potentially worth over $475 million, granting the pharma giant ...

Researchers are working on microscopic, wireless chips that can travel through the bloodstream and self-implant in a targeted ...

CMS's Abe Sutton said GENEROUS aims to ensure that Medicaid pricing will be on par with that in other developed nations.

MeiraGTx’s AAV-AIPL1 has already led to vision gains in blind children, as regulatory submissions for the gene therapy close ...

Lilly will also gain certain rights to MeiraGTx’s proprietary riboswitch technology for use in gene editing in the eye. Under ...

Eli Lilly shares are rising Monday after Leerink Partners upgraded the stock to Outperform and raised its price target to ...

Eli Lilly is partnering with MeiraGTx to develop and commercialize ophthalmology gene therapies, and with SanegeneBio to ...

Market Catalysts host Julie Hyman tracks several of the day's top trending stock tickers, including Plug Power (PLUG) ...

MeiraGTx (MGTX) stock climbs as the company partners with Eli Lilly (LLY) to develop and sell gene therapies for eye diseases ...

Eli Lilly has penned a research pact worth $1.2 billion in biobucks with SanegeneBio to help pinpoint cardiometabolic RNAi ...

Eli Lilly will partner with Insilico Medicine on an artificial intelligence (AI)-based drug development collaboration that they said could generate “over $100 million” for the AI drug discovery ...

Choose Boston Business Journal as a preferred news source to see more of our reporting on Google. The deal could mean over ...